VRDN – viridian therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Viridian Therapeutics' Superior Prospects Make It A Buy [Seeking Alpha]
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - Global Forecast to 2030 [Yahoo! Finance]
Form 8-K Viridian Therapeutics, For: Nov 12
Form 10-Q Viridian Therapeutics, For: Sep 30
Form SC 13G/A Viridian Therapeutics, Filed by: STATE STREET CORP
Form 4 Viridian Therapeutics, For: Sep 27 Filed by: Beetham Thomas W.
Form 4 Viridian Therapeutics, For: Sep 27 Filed by: Mahoney Stephen F.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.